A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG, Amgen (Neupogen)

Final Accrual

20

Trial Chairperson

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Clinical Trial Registration

Related Post

22 June, 2026

Novel lung cancer radiation therapy approach to be tested in new PRIME-Lung trial

LATEST NEWS: 22 June 2026 In an important step

Facility Alliance Member in Focus
17 June, 2026

TROG Facility Alliance Member in Focus: Radiation Oncology Network, Western Sydney Local Health District

TROG’s Facility Alliance Members (FAM) are the cornerstone of